4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: Evaluation using a fillable kidney phantom imaged by90Y PET

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1969-1973

  Walrand, Stephan ^a   Jamar, François ^a   Van Elmbt, Larry ^a   Lhommel, Renaud ^a   Bekonde, Edgar Bidja'a ^a   Pauwels, Stanislas ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

90Y; Dosimetry; Kidney; PET; PET CT; PRRT; Radiobiology dosimetry; Radionuclide therapy

Indexed keywords

YTTRIUM 90;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; GEOMETRY; KIDNEY CORTEX; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; SPLEEN;

HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KIDNEY CORTEX; LIVER; LUTETIUM; PHANTOMS, IMAGING; RADIOMETRY; RECEPTORS, PEPTIDE; SILICATES; YTTRIUM RADIOISOTOPES;

EID: 78651268904     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.080093     Document Type: Article

References (24)

1. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer. 2006;42:994-1003.
2. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):13S-17S.
3. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1):99S-106S.
4. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):92S-98S.
5. Flux G, Bardies M, Monsieurs M, Savolainen S, Strand SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16:47-59.
6. Flux G, Bardies M, Chiesa C, et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray." Eur J Nucl Med Mol Imaging. 2007;34:1699-1700.
7. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray." Eur J Nucl Med Mol Imaging. 2007;34:772-786.
8. Sgouros G, Frey E, Wahl R, et al. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med. 2008;38:321-334.
9. Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med. 2008;38:308-320.
10. Minarik D, Gleisner KS, Ljungberg M. Evaluation of quantitative Y-90 SPECT based on experimental phantom studies. Phys Med Biol. 2008;53:5689-5703.
11. Sgouros G. Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis. Med Phys. 1998;25:1487-1490.
12. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.
13. Walrand S, Jamar F, Mathieu I, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging. 2003;30:354-361.
14. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,o-Phel,Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368-371.
15. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467-1475.
16. Ford K. Predicted 0+ level of Zr90. Phys Rev. 1955;98:1516.
17. Nickles RJ, Roberts AD, Nye JA, et al. Assaying and PET imaging of yttrium-90: 1≫34ppm>0. IEEE Nucl Sci Symp Rec. 2004;6:3412-3414.
18. Lhommel R, Goffette P, Van den Eynde M, et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging. 2009;36:1696.
19. 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur J Nucl Med Mol Imaging. 2009;37:407-408.
20. Lhommel R, van Elmbt L, Goffette P, Van et al. Feasibility of yttrium-90 TOF-PET based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654-1662.
21. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-1147.
22. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171.
23. Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48:134-142.
24. Rault E, Clementel E, Vandenberghe S, et al. Comparison of yttrium-90 SPECT and PET images [abstract]. J Nucl Med. 2010;51(suppl 2):125.